| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3405386 | Journal des Anti-infectieux | 2011 | 10 Pages |
Abstract
Treatment of latent tuberculosis infection is a key component of tuberculosis control programs. We describe here the benefit to risk ratio of this therapy at the individual and collective levels. Acceptance and adherence influence the efficiency of this treatment. A close follow-up of the patients is necessary to avoid toxicity. Isoniazid monotherapy for 6 to 9 months or isoniazid plus rifampin for 3 months are the most commonly used regimens. French guidelines are presented.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
P. Fraisse,